Global Cancer Biomarkers Market Overview:
Global Cancer Biomarkers Market is expected to grow at a significant rate during the forecast period 2026-2035, with 2024 as the base year.
Global Cancer Biomarkers Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Cancer Biomarkers involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Cancer Biomarkers Market:
The Cancer Biomarkers Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Cancer Biomarkers Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Cancer Biomarkers Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Cancer Biomarkers market has been segmented into:
CA 125
HER2
EGFR
CD20
BRAF
Calcitonin
Others
By Application, Cancer Biomarkers market has been segmented into:
Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Head & neck Cancer
Non-small Cell Lung Cancer
Other Cancers
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Cancer Biomarkers market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Cancer Biomarkers market.
Top Key Players Covered in Cancer Biomarkers market are:
bioMérieux Inc.
INOVIQ
Bio-Rad Laboratories Inc.
Abbott
Becton Dickinson and Company
Merck KgaA
QIAGEN N.V.
Thermo Fisher Scientific Inc.
CENTOGENE N.V.
PerkinElmer Inc.
Siemens Healthineers
F. Hoffmann-la Roche Ltd
Agilent Technologiesinc
Invitae Corporation
Myriad Genetics
Guardant Health
Illumina
FOUNDATION MEDICINEinc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Cancer Biomarkers Market by Type
4.1 Cancer Biomarkers Market Snapshot and Growth Engine
4.2 Cancer Biomarkers Market Overview
4.3 CA 125
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 CA 125: Geographic Segmentation Analysis
4.4 HER2
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 HER2: Geographic Segmentation Analysis
4.5 EGFR
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 EGFR: Geographic Segmentation Analysis
4.6 CD20
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 CD20: Geographic Segmentation Analysis
4.7 BRAF
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 BRAF: Geographic Segmentation Analysis
4.8 Calcitonin
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Calcitonin: Geographic Segmentation Analysis
4.9 Others
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Others: Geographic Segmentation Analysis
Chapter 5: Cancer Biomarkers Market by Application
5.1 Cancer Biomarkers Market Snapshot and Growth Engine
5.2 Cancer Biomarkers Market Overview
5.3 Breast Cancer
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Breast Cancer: Geographic Segmentation Analysis
5.4 Lung Cancer
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Lung Cancer: Geographic Segmentation Analysis
5.5 Prostate Cancer
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Prostate Cancer: Geographic Segmentation Analysis
5.6 Kidney Cancer
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Kidney Cancer: Geographic Segmentation Analysis
5.7 Liver Cancer
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Liver Cancer: Geographic Segmentation Analysis
5.8 Head & neck Cancer
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Head & neck Cancer: Geographic Segmentation Analysis
5.9 Non-small Cell Lung Cancer
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Non-small Cell Lung Cancer: Geographic Segmentation Analysis
5.10 Other Cancers
5.10.1 Introduction and Market Overview
5.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.10.3 Key Market Trends, Growth Factors and Opportunities
5.10.4 Other Cancers: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Cancer Biomarkers Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 BIOMÉRIEUX INC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 INOVIQ
6.4 BIO-RAD LABORATORIES INC.
6.5 ABBOTT
6.6 BECTON DICKINSON AND COMPANY
6.7 MERCK KGAA
6.8 QIAGEN N.V.
6.9 THERMO FISHER SCIENTIFIC INC.
6.10 CENTOGENE N.V.
6.11 PERKINELMER INC.
6.12 SIEMENS HEALTHINEERS
6.13 F. HOFFMANN-LA ROCHE LTD
6.14 AGILENT TECHNOLOGIESINC
6.15 INVITAE CORPORATION
6.16 MYRIAD GENETICS
6.17 GUARDANT HEALTH
6.18 ILLUMINA
6.19 FOUNDATION MEDICINEINC.
Chapter 7: Global Cancer Biomarkers Market By Region
7.1 Overview
7.2. North America Cancer Biomarkers Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 CA 125
7.2.4.2 HER2
7.2.4.3 EGFR
7.2.4.4 CD20
7.2.4.5 BRAF
7.2.4.6 Calcitonin
7.2.4.7 Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Breast Cancer
7.2.5.2 Lung Cancer
7.2.5.3 Prostate Cancer
7.2.5.4 Kidney Cancer
7.2.5.5 Liver Cancer
7.2.5.6 Head & neck Cancer
7.2.5.7 Non-small Cell Lung Cancer
7.2.5.8 Other Cancers
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Cancer Biomarkers Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 CA 125
7.3.4.2 HER2
7.3.4.3 EGFR
7.3.4.4 CD20
7.3.4.5 BRAF
7.3.4.6 Calcitonin
7.3.4.7 Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Breast Cancer
7.3.5.2 Lung Cancer
7.3.5.3 Prostate Cancer
7.3.5.4 Kidney Cancer
7.3.5.5 Liver Cancer
7.3.5.6 Head & neck Cancer
7.3.5.7 Non-small Cell Lung Cancer
7.3.5.8 Other Cancers
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Cancer Biomarkers Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 CA 125
7.4.4.2 HER2
7.4.4.3 EGFR
7.4.4.4 CD20
7.4.4.5 BRAF
7.4.4.6 Calcitonin
7.4.4.7 Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Breast Cancer
7.4.5.2 Lung Cancer
7.4.5.3 Prostate Cancer
7.4.5.4 Kidney Cancer
7.4.5.5 Liver Cancer
7.4.5.6 Head & neck Cancer
7.4.5.7 Non-small Cell Lung Cancer
7.4.5.8 Other Cancers
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Cancer Biomarkers Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 CA 125
7.5.4.2 HER2
7.5.4.3 EGFR
7.5.4.4 CD20
7.5.4.5 BRAF
7.5.4.6 Calcitonin
7.5.4.7 Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Breast Cancer
7.5.5.2 Lung Cancer
7.5.5.3 Prostate Cancer
7.5.5.4 Kidney Cancer
7.5.5.5 Liver Cancer
7.5.5.6 Head & neck Cancer
7.5.5.7 Non-small Cell Lung Cancer
7.5.5.8 Other Cancers
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Cancer Biomarkers Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 CA 125
7.6.4.2 HER2
7.6.4.3 EGFR
7.6.4.4 CD20
7.6.4.5 BRAF
7.6.4.6 Calcitonin
7.6.4.7 Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Breast Cancer
7.6.5.2 Lung Cancer
7.6.5.3 Prostate Cancer
7.6.5.4 Kidney Cancer
7.6.5.5 Liver Cancer
7.6.5.6 Head & neck Cancer
7.6.5.7 Non-small Cell Lung Cancer
7.6.5.8 Other Cancers
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Cancer Biomarkers Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 CA 125
7.7.4.2 HER2
7.7.4.3 EGFR
7.7.4.4 CD20
7.7.4.5 BRAF
7.7.4.6 Calcitonin
7.7.4.7 Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Breast Cancer
7.7.5.2 Lung Cancer
7.7.5.3 Prostate Cancer
7.7.5.4 Kidney Cancer
7.7.5.5 Liver Cancer
7.7.5.6 Head & neck Cancer
7.7.5.7 Non-small Cell Lung Cancer
7.7.5.8 Other Cancers
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Cancer Biomarkers Scope:
|
Report Data
|
Cancer Biomarkers Market
|
|
Cancer Biomarkers Market Size in 2025
|
USD XX million
|
|
Cancer Biomarkers CAGR 2025 - 2032
|
XX%
|
|
Cancer Biomarkers Base Year
|
2024
|
|
Cancer Biomarkers Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
bioMérieux Inc., INOVIQ, Bio-Rad Laboratories Inc., Abbott, Becton Dickinson and Company, Merck KgaA, QIAGEN N.V., Thermo Fisher Scientific Inc., CENTOGENE N.V., PerkinElmer Inc., Siemens Healthineers, F. Hoffmann-la Roche Ltd, Agilent Technologiesinc, Invitae Corporation, Myriad Genetics, Guardant Health, Illumina, FOUNDATION MEDICINEinc..
|
|
Key Segments
|
By Type
CA 125
HER2
EGFR
CD20
BRAF
Calcitonin
Others
By Applications
Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Head & neck Cancer
Non-small Cell Lung Cancer
Other Cancers
|
